David Ricks, Eli Lilly CEO (Al Drago/Bloomberg via Getty Images)
Updated: Eli Lilly's Mounjaro sales hit $1.4B for the quarter, but FDA decision on Alzheimer's drug is delayed
Eli Lilly raked in $9.5 billion in sales in the third quarter, shooting up 37% year-over-year thanks in part to growing sales of its new …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
